Kiniksa Pharmaceuticals International (KNSA) Gross Profit (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Gross Profit for 6 consecutive years, with $220.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 59.22% year-over-year to $220.0 million; the trailing twelve-month figure through Jun 2026 stood at $755.3 million (up 66.05% YoY), and the FY2025 full-year result was $599.9 million, up 65.57% from the prior year.
• Gross Profit improved to $220.0 million in Q2 2026 per KNSA's latest filing, from $193.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $220.0 million in Q2 2026 and bottomed at $21.9 million in Q2 2022.
• Historically, Gross Profit has averaged $100.5 million across 5 years, with a median of $92.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Gross Profit soared 888.4% in 2022, then tumbled 37.14% in 2023.
• Over 5 years, Gross Profit stood at $55.2 million in 2022, then jumped by 33.78% to $73.8 million in 2023, then jumped by 41.77% to $104.6 million in 2024, then surged by 73.15% to $181.2 million in 2025, then climbed by 21.44% to $220.0 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $220.0 million, $193.5 million, and $181.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.